Study on F9 gene expression downregulation and its clinical value in hepatocellular carcinoma.
10.3760/cma.j.cn501113-20230423-00191
- Author:
Li LI
1
;
Mao GUO
1
;
Yang XIA
2
;
Qiong Fang ZHANG
1
;
Ling AO
1
;
Da Zhi ZHANG
1
Author Information
1. Department of lnfectious Diseases, the Second Affiliated Hospital of Chongqing Medical University, Chongqing 401336, China.
2. Department of Urology, the Second Affiliated Hospital of Chongqing Medical University, Chongqing 401336, China.
- Publication Type:Journal Article
- Keywords:
Bioinformatics;
F9 gene;
Gene chips;
Hepatocellular carcinoma;
Public data platform
- MeSH:
Humans;
Carcinoma, Hepatocellular/pathology*;
Liver Neoplasms/pathology*;
Down-Regulation;
Prognosis;
Gene Expression;
Gene Expression Regulation, Neoplastic
- From:
Chinese Journal of Hepatology
2023;31(7):716-722
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To analyze the expression levels of the F9 gene and F9 protein in hepatocellular carcinoma by combining multiple gene chip data, real-time fluorescence quantitative PCR (RT qPCR), and immunohistochemistry. Additionally, explore their correlation with the occurrence and development of hepatocellular carcinoma, as well as with various clinical indicators and prognosis. Methods: The mRNA microarray dataset from the GEO database was analyzed to identify the F9 gene with significant expression differences associated with hepatocellular carcinoma. Liver cancer and adjacent tissues were collected from 18 cases of hepatocellular carcinoma. RT-qPCR method was used to detect the F9 gene expression level. Immunohistochemistry was used to detect the F9 protein level. Combined with the TCGA database information, the correlation between F9 gene expression level and prognostic and clinicopathological parameters was analyzed. The biological function of F9 co-expressed genes associated with hepatocellular carcinoma was analyzed by the Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG). Statistical analysis was performed using Graphpad Prism software. Results: Meta-analysis results showed that the expression of the F9 gene was lower in HCC tissues than in non-cancerous tissues. Immunohistochemistry results were basically consistent with those of RT-qPCR. The data obtained from TCGA showed that the F9 gene had lower expression values in stages III-IV, T3-T4, and patients with vascular invasion. A total of 127 genes were selected for bioinformatics analysis as co-expressed genes of F9, which were highly enriched in redox processes and metabolic pathways. Conclusion: This study validates that the F9 gene and F9 protein are lower in HCC. The down-regulation of the F9 gene predicts adverse outcomes, which may provide a new therapeutic target for HCC.
